Select Page

Asia Market Access

CSOFT provides Asia market access consulting to our clients so they can gain a better understanding of how to approach this dynamic yet challenging market.

Contact us now
Home 9 Asia Regulatory Services 9 Asia Market Access

China’s pharmaceutical market is the second-largest in the world, with multiple clinical trial sites and constant development of regulatory reforms, making it worth billions of dollars and a valuable investment for companies that can successfully gain Asia market access. 

China Health Trends

Highly prevalent diseases

Patients statistics & demographics

Unmet clinical needs

Medical market value

Breakthroughs & Innovations

Clinical trials landscape

Drug discovery innovation

New technology & development

Hot topics

Regulatory Framework

Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA)

2019 China’s new drug administration law

Healthcare system

China regulatory reforms

Asia Market Access: Methodology


  • Data analytics & evaluation skills
  • Product gap analysis
  • Access to first-hand
    market data & intelligence
  • Access to first-hand
    market data & intelligence


  • Market research reports
  • Data summaries
  • Proposals
  • Comments & feedback

Asia Market Access Consulting

  • Medical market
  • Healthcare system
  • Pharmaceutical regulations
  • Latest updates and revisions to regulations
  • Cultural and linguistic differences


  • RA executives
  • International marketing and sales team
  • Key opinion leaders (KOLs)
  • Local experts in NMPA regulations and clinical trials in China market